See more : Three’s Company Media Group Co., Ltd. (605168.SS) Income Statement Analysis – Financial Results
Complete financial analysis of IGM Biosciences, Inc. (IGMS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IGM Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Unity Enterprise Holdings Limited (2195.HK) Income Statement Analysis – Financial Results
- Trustpilot Group plc (TRST.L) Income Statement Analysis – Financial Results
- Ubon Bio Ethanol Public Company Limited (UBE.BK) Income Statement Analysis – Financial Results
- Finger, Inc. (163730.KQ) Income Statement Analysis – Financial Results
- HHG Capital Corporation (HHGCW) Income Statement Analysis – Financial Results
IGM Biosciences, Inc. (IGMS)
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.13M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| Gross Profit | -6.15M | -9.53M | -7.72M | -3.58M | -2.33M | -278.00K | -161.00K |
| Gross Profit Ratio | -288.59% | -891.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 215.52M | 179.29M | 127.03M | 65.03M | 35.26M | 18.96M | 8.64M |
| General & Administrative | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Other Expenses | 0.00 | -181.00K | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Operating Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Cost & Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Interest Income | 17.74M | 7.04M | 159.00K | 1.93M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| EBITDA | -253.36M | -221.88M | -157.44M | -77.78M | -40.80M | -22.51M | -10.99M |
| EBITDA Ratio | -11,894.74% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -263.46M | -227.96M | -165.32M | -83.28M | -44.50M | -22.79M | -11.15M |
| Operating Income Ratio | -12,369.06% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.72M | 6.85M | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Income Before Tax | -245.74M | -221.10M | -165.16M | -81.36M | -43.13M | -22.71M | -11.05M |
| Income Before Tax Ratio | -11,537.00% | -20,683.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 678.00K | -6.85M | -4.48M | -1.03M | -597.00K | 80.00K | 0.00 |
| Net Income | -246.42M | -214.25M | -160.68M | -80.33M | -42.54M | -22.71M | -11.05M |
| Net Income Ratio | -11,568.83% | -20,041.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| EPS Diluted | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| Weighted Avg Shares Out | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
| Weighted Avg Shares Out (Dil) | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)
Resolutions at the Annual General Meeting in Medivir on 4 May 2023
IGM Biosciences to Present at Two Upcoming Investor Conferences
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023
IGM Biosciences, Inc. (IGMS) Q4 2022 Earnings Call Transcript
Notice of Annual General Meeting of Medivir AB (publ)
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports